Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Non-Current Assets for 10 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 232.59% to $5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.6 million, a 232.59% increase, with the full-year FY2024 number at $1.7 million, up 21.21% from a year prior.
  • Other Non-Current Assets was $5.6 million for Q3 2025 at Cartesian Therapeutics, up from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.6 million in Q3 2025 to a low of $1.3 million in Q1 2023.
  • A 5-year average of $1.7 million and a median of $1.4 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: fell 13.94% in 2023, then skyrocketed 232.59% in 2025.
  • Cartesian Therapeutics' Other Non-Current Assets stood at $1.4 million in 2021, then rose by 16.03% to $1.6 million in 2022, then decreased by 13.94% to $1.4 million in 2023, then rose by 21.21% to $1.7 million in 2024, then surged by 232.59% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Other Non-Current Assets are $5.6 million (Q3 2025), $1.7 million (Q2 2025), and $1.7 million (Q4 2024).